HK1139861A1 - 磷酸二酯酶 抑制劑用在治療肢體活動障礙 - Google Patents
磷酸二酯酶 抑制劑用在治療肢體活動障礙Info
- Publication number
- HK1139861A1 HK1139861A1 HK10106488.4A HK10106488A HK1139861A1 HK 1139861 A1 HK1139861 A1 HK 1139861A1 HK 10106488 A HK10106488 A HK 10106488A HK 1139861 A1 HK1139861 A1 HK 1139861A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pde7
- treatment
- movement disorders
- inhibitors
- pde7 inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92049607P | 2007-03-27 | 2007-03-27 | |
PCT/US2008/058530 WO2008119057A2 (en) | 2007-03-27 | 2008-03-27 | The use of pde7 inhibitors for the treatment of movement disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1139861A1 true HK1139861A1 (zh) | 2010-09-30 |
Family
ID=39789284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10106488.4A HK1139861A1 (zh) | 2007-03-27 | 2010-07-05 | 磷酸二酯酶 抑制劑用在治療肢體活動障礙 |
Country Status (13)
Country | Link |
---|---|
US (3) | US20080260643A1 (zh) |
EP (1) | EP2139475B1 (zh) |
JP (2) | JP5580192B2 (zh) |
CN (2) | CN104758291B (zh) |
AU (1) | AU2008230710B2 (zh) |
BR (1) | BRPI0809244A2 (zh) |
CA (1) | CA2681650C (zh) |
ES (1) | ES2533206T3 (zh) |
HK (1) | HK1139861A1 (zh) |
MX (1) | MX2009010450A (zh) |
NZ (1) | NZ580413A (zh) |
RU (1) | RU2449790C2 (zh) |
WO (1) | WO2008119057A2 (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
WO2010111060A1 (en) * | 2009-03-23 | 2010-09-30 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
FR2943673B1 (fr) * | 2009-03-27 | 2013-03-29 | Sanofi Aventis | Applications therapeutiques de derives de quinazolinedione |
FR2944282B1 (fr) | 2009-04-09 | 2013-05-03 | Sanofi Aventis | Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques |
FR2944206B1 (fr) | 2009-04-09 | 2012-12-28 | Sanofi Aventis | Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione |
AU2013202493B2 (en) * | 2009-05-04 | 2016-03-10 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
ES2353093B1 (es) * | 2009-05-20 | 2012-01-03 | Consejo Superior De Investigaciones Científicas (Csic) | Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas. |
ES2360783B1 (es) | 2009-10-02 | 2012-07-04 | Consejo Superior De Investigaciones Científicas (Csic) | 1,2,4-tiadiazoles-5-imino sustituidos utiles en el tratamiento de enfermedades neurodegenerativas |
US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
KR102385359B1 (ko) | 2010-11-08 | 2022-04-11 | 오메로스 코포레이션 | Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료 |
DK2846805T3 (en) * | 2012-05-07 | 2019-03-18 | Omeros Corp | TREATMENT OF DEPENDENCE AND IMPULSE CONTROL DISORDERS USING PDE7 INHIBITORS |
IN2014DN10404A (zh) * | 2012-05-07 | 2015-08-14 | Omeros Corp | |
WO2018038265A1 (ja) * | 2016-08-26 | 2018-03-01 | 田辺三菱製薬株式会社 | 二環式含窒素複素環化合物 |
US20210330736A1 (en) * | 2018-09-05 | 2021-10-28 | Universiteit Van Amsterdam | Use of a pde11 or pde2 inhibitor for the treatment of parkinson's disease |
WO2024038090A1 (en) | 2022-08-18 | 2024-02-22 | Mitodicure Gmbh | Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5453566A (en) | 1986-03-28 | 1995-09-26 | Calgene, Inc. | Antisense regulation of gene expression in plant/cells |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
DE3852539T3 (de) | 1987-12-15 | 2005-08-04 | Gene Shears Pty. Ltd. | Ribozyme. |
GB8822492D0 (en) | 1988-09-24 | 1988-10-26 | Considine J | Apparatus for removing tumours from hollow organs of body |
US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
IL108367A0 (en) | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
US5739119A (en) | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
US5932465A (en) * | 1997-10-16 | 1999-08-03 | Icos Corporation | Phosphodiesterase 8A |
ATE331791T1 (de) * | 1998-02-23 | 2006-07-15 | Icos Corp | Phosphodiesterase 10 |
ATE371740T1 (de) * | 1998-12-23 | 2007-09-15 | Pfizer | Phosphodiesterasen |
WO2000068230A1 (en) | 1999-05-05 | 2000-11-16 | Darwin Discovery Limited | 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7 inhibitors |
US6627651B1 (en) | 1999-05-07 | 2003-09-30 | Takeda Chemical Industries, Ltd. | Cyclic compounds and uses thereof |
US6146876A (en) | 1999-06-11 | 2000-11-14 | Millennium Pharmaceuticals, Inc. | 22025, a novel human cyclic nucleotide phosphodiesterase |
DE19950647A1 (de) | 1999-10-21 | 2001-04-26 | Merck Patent Gmbh | Imidazolderivate als Phosphodiesterase VII-Hemmer |
US7491742B2 (en) * | 1999-10-21 | 2009-02-17 | Merck Patent Gmbh | Imidazole derivatives as phosphodiesterase VII inhibitors |
DE19953025A1 (de) * | 1999-11-04 | 2001-05-10 | Merck Patent Gmbh | Pyrrolderivate als Phosphodiesterase VII-Hemmer |
DE19953024A1 (de) * | 1999-11-04 | 2001-05-10 | Merck Patent Gmbh | Isoxazolderivate als Phosphodiesterase VII-Hemmer |
DE19953414A1 (de) | 1999-11-06 | 2001-05-10 | Merck Patent Gmbh | Imidazopyridinderivate als Phospodiesterase VII-Hemmer |
DE19954707A1 (de) * | 1999-11-13 | 2001-05-17 | Merck Patent Gmbh | Imidazolverbindungen als Phosphodiesterase VII-Hemmer |
US6649592B1 (en) | 2000-01-14 | 2003-11-18 | Science & Technology Corporation @ Unm | Peptide inhibitors of LFA-1/ICAM-1 interaction |
JP2003523405A (ja) * | 2000-02-22 | 2003-08-05 | セレジー カナダ インコーポレイテッド | 睡眠改善のための方法および組成物 |
WO2001062904A1 (en) | 2000-02-24 | 2001-08-30 | Bayer Aktiengesellschaft | Regulation of human gelatinase b-like enzyme 1 |
GB0007934D0 (en) | 2000-03-31 | 2000-05-17 | Darwin Discovery Ltd | Chemical compounds |
US7345031B2 (en) * | 2000-04-12 | 2008-03-18 | International Medical Innovations, Inc. | Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation and use |
GB0015095D0 (en) | 2000-06-20 | 2000-08-09 | Celltech Chiroscience Ltd | Chemical compounds |
AU2001286832A1 (en) | 2000-08-30 | 2002-03-13 | Lilly Icos Llc | Method for treatment of migraine using PDE5 inhibitors |
EP1193261A1 (en) * | 2000-10-02 | 2002-04-03 | Warner-Lambert Company | New thiadiazoles and their use as phosphodiesterase-7 inhibitors |
CN1474812A (zh) | 2000-11-14 | 2004-02-11 | �ȿˡ��Ŷ��١���ķ������ѧ��˾ | 用作磷酸二酯酶抑制剂的(二氢)异喹啉衍生物 |
AU2002224835A1 (en) | 2000-11-14 | 2002-05-27 | Byk Gulden Lomberg Chemische Fabrik G.M.B.H. | Dihydroisoquinolines as novel phosphodiesterase inhibitors |
IL140844A0 (en) * | 2001-01-10 | 2002-02-10 | Polygene Ltd | Cationic polysaccharide compositions |
WO2002069905A2 (en) * | 2001-03-02 | 2002-09-12 | Bristol-Myers Squibb Company | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders |
US6617357B2 (en) * | 2001-03-06 | 2003-09-09 | Smithkline Beecham Corporation | Compounds and their use as PDE inhibitors |
AP1699A (en) * | 2001-03-21 | 2006-12-26 | Warner Lambert Co | New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors |
CA2445188A1 (en) | 2001-04-18 | 2002-10-31 | Ortho-Mcneil Pharmaceutical, Inc. | Arylindenopyridines with pde inhibiting activity |
US6958328B2 (en) | 2001-04-18 | 2005-10-25 | Ortho-Mcneil Pharmaceutical, Inc | Arylindenopyridines and related therapeutic and prophylactic methods |
US6903109B2 (en) | 2001-04-18 | 2005-06-07 | Ortho-Muniel Pharmaceutical, Inc. | Arylindenopyridines and related therapeutic and prophylactic methods |
US20030032579A1 (en) * | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
CN1503792A (zh) * | 2001-04-25 | 2004-06-09 | ��̹��ҽҩ��˾ | 新的酞嗪酮 |
US20030053980A1 (en) | 2001-04-30 | 2003-03-20 | The Gillette Company | Shaving compositions containing highly lubricious water soluble polymers |
US6849638B2 (en) | 2001-04-30 | 2005-02-01 | Bayer Pharmaceuticals Corporation | 4-amino-5,6-substituted thiopheno [2,3-d] pyrimidines, pharmaceutical compositions containing the same, and their use in the treatment or prevention of pde7b-mediated diseases and conditions |
WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
RU2285002C2 (ru) * | 2001-06-15 | 2006-10-10 | Астеллас Фарма Инк. | Производное пиридина и фармацевтическая композиция на его основе |
HUP0402352A2 (hu) | 2001-06-19 | 2005-02-28 | Bristol-Myers Squibb Co. | Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények |
PE20030008A1 (es) * | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
DE10130167A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Imidazotriazine |
WO2003020702A2 (en) * | 2001-08-31 | 2003-03-13 | The Rockefeller University | Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain |
US20060286622A1 (en) * | 2001-09-28 | 2006-12-21 | Patricia Soulard | Polypeptides exhibiting PDE7 activity and their use for selecting compounds which inhibit PDE 7 enzyme activity |
KR100929513B1 (ko) | 2001-12-13 | 2009-12-03 | 아스비오파마 가부시키가이샤 | Pde7 저해 작용을 갖는 피라졸로피리미디논 유도체 |
DE10163991A1 (de) * | 2001-12-24 | 2003-07-03 | Merck Patent Gmbh | Pyrrolo-pyrimidine |
AU2002360774A1 (en) | 2001-12-28 | 2003-07-24 | Bayer Corporation | 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones |
US7378428B2 (en) | 2002-01-31 | 2008-05-27 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient |
US20040082061A1 (en) * | 2002-02-14 | 2004-04-29 | Anna Astromoff | Drug metabolizing enzymes |
EP1348701A1 (en) * | 2002-03-28 | 2003-10-01 | Warner-Lambert Company LLC | (2,4-disubstituted-thiazol-5-yl) amine compounds as PDE7 inhibitors |
EP1348433A1 (en) * | 2002-03-28 | 2003-10-01 | Warner-Lambert Company LLC | Thiazol-2-yl-imine compounds as PDE-7 inhibitors |
EP1400244A1 (en) * | 2002-09-17 | 2004-03-24 | Warner-Lambert Company LLC | New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors |
WO2004044196A1 (en) | 2002-11-13 | 2004-05-27 | Bayer Healthcare Ag | DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7B (PDE7b) |
ES2217956B1 (es) | 2003-01-23 | 2006-04-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. |
US7217527B2 (en) * | 2003-04-15 | 2007-05-15 | Vanderbilt University | Assay for phosphodiesterase function |
JP2006219374A (ja) * | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Pde7阻害作用を有するイミダゾトリアジノン誘導体 |
JP2006219373A (ja) * | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体 |
US20050130971A1 (en) * | 2003-08-22 | 2005-06-16 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury |
US7932250B2 (en) | 2004-07-01 | 2011-04-26 | Daiichi Sankyo Company, Limited | Thienopyrazole derivative having PDE7 inhibitory activity |
CA2599662A1 (en) * | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of pde7 inhibitors for the treatment of neuropathic pain |
WO2006092692A1 (en) | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain |
JP2009512711A (ja) * | 2005-10-21 | 2009-03-26 | ブレインセルス,インコーポレイティド | Pde阻害による神経新生の調節 |
JP2009517453A (ja) * | 2005-12-02 | 2009-04-30 | ファイザー・リミテッド | Pde7阻害剤としてのスピロ環式キナゾリン誘導体 |
US8637528B2 (en) * | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
-
2008
- 2008-03-27 MX MX2009010450A patent/MX2009010450A/es active IP Right Grant
- 2008-03-27 NZ NZ580413A patent/NZ580413A/xx unknown
- 2008-03-27 BR BRPI0809244-3A patent/BRPI0809244A2/pt not_active Application Discontinuation
- 2008-03-27 WO PCT/US2008/058530 patent/WO2008119057A2/en active Application Filing
- 2008-03-27 JP JP2010501232A patent/JP5580192B2/ja active Active
- 2008-03-27 ES ES08744515.1T patent/ES2533206T3/es active Active
- 2008-03-27 US US12/057,368 patent/US20080260643A1/en not_active Abandoned
- 2008-03-27 AU AU2008230710A patent/AU2008230710B2/en active Active
- 2008-03-27 CN CN201510082785.6A patent/CN104758291B/zh active Active
- 2008-03-27 CA CA2681650A patent/CA2681650C/en active Active
- 2008-03-27 EP EP08744515.1A patent/EP2139475B1/en active Active
- 2008-03-27 CN CN200880017058XA patent/CN101917992A/zh active Pending
- 2008-03-27 RU RU2009138966/15A patent/RU2449790C2/ru active
-
2010
- 2010-07-05 HK HK10106488.4A patent/HK1139861A1/zh unknown
- 2010-12-21 US US12/974,693 patent/US20110091388A1/en not_active Abandoned
-
2014
- 2014-05-28 JP JP2014109910A patent/JP5943964B2/ja active Active
-
2018
- 2018-12-06 US US16/212,064 patent/US20190183824A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2009138966A (ru) | 2011-05-10 |
AU2008230710B2 (en) | 2014-04-10 |
CA2681650A1 (en) | 2008-10-02 |
CN101917992A (zh) | 2010-12-15 |
MX2009010450A (es) | 2009-11-23 |
JP2010522768A (ja) | 2010-07-08 |
RU2449790C2 (ru) | 2012-05-10 |
CA2681650C (en) | 2016-11-22 |
JP5943964B2 (ja) | 2016-07-05 |
EP2139475A2 (en) | 2010-01-06 |
BRPI0809244A2 (pt) | 2014-09-23 |
AU2008230710A1 (en) | 2008-10-02 |
EP2139475A4 (en) | 2012-03-07 |
WO2008119057A3 (en) | 2008-11-20 |
WO2008119057A2 (en) | 2008-10-02 |
US20080260643A1 (en) | 2008-10-23 |
EP2139475B1 (en) | 2014-12-17 |
CN104758291A (zh) | 2015-07-08 |
JP5580192B2 (ja) | 2014-08-27 |
US20190183824A1 (en) | 2019-06-20 |
JP2014198718A (ja) | 2014-10-23 |
ES2533206T3 (es) | 2015-04-08 |
NZ580413A (en) | 2012-11-30 |
CN104758291B (zh) | 2020-03-03 |
US20110091388A1 (en) | 2011-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1139861A1 (zh) | 磷酸二酯酶 抑制劑用在治療肢體活動障礙 | |
HRP20181608T1 (hr) | Korištenje inhibitora pde7 u liječenju bolesti kretanja | |
IL185485A0 (en) | Use of pde7 inhibitors for the treatment of neuropathic pain | |
GB2453188B (en) | Use of compounds in the manufacture of medicaments for treatment of regional fat deposits | |
EP1874286A4 (en) | METHOD AND COMPOSITIONS FOR TREATING ANXIETY STATE | |
IL193936A0 (en) | Compositions and methods for the treatment of immunoinflammatory disorders | |
IL195152A (en) | Compounds for use in treating diseases of cell culture | |
IL195906A0 (en) | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | |
HK1129426A1 (zh) | 用於治療肺部病症的酶的合成物 | |
EP1996218A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | |
IL205578A0 (en) | Aldh-2 inhibitors in the treatment of psychiatric disorders | |
ZA200806455B (en) | Use of 2-imidazoles for the treatment of CNS disorders | |
PT2054045E (pt) | Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento da artrite e da dor | |
IL188390A0 (en) | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders | |
EP2077838A4 (en) | METHODS FOR TREATING A-RELATED DISORDERS AND COMPOSITIONS THEREFOR | |
HK1134032A1 (en) | New combination for use in the treatment of inflammatory disorders | |
EP2007790A4 (en) | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN | |
IL192877A0 (en) | Use of 2-imidazoles for the treatment of cns disorders | |
IL192933A0 (en) | Benzoisoindole derivatives for the treatment of pain | |
GB0620695D0 (en) | Composition and methods for the treatment of nurdegenerative disease | |
IL193943A0 (en) | The use of beta- aminoalcohols for the treatment of inflammatory disorders and pain | |
GB0710277D0 (en) | Use of antivirals in the treatment of medical disorders | |
EP2370087A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF FLUID RETENTION DISORDERS | |
ZA200707147B (en) | Use of PDE7 inhibitors for the treatment of neuropathic pain | |
IL193944A0 (en) | The use beta-aminoalcohols for the treatment of inflammatory disorders and pain |